SavedAdd your journal

Journals / Journal of Contemporary Medicine / 2022 / Cilt: 12 - Sayı: 1

A comparative study of VITEK-2, Double Disc Synergy and Combined Disc Methods for detection of ESBL (Extended Spectrum Beta-Lactamase) production in Escherichia coli and Klebsiella pneumoniae strains

Mustafa YILMAZ
Öznur AK
Demet HACISEYİTOĞLU
Sevil ALKAN
Pages
116–120
Publication Date
2022-01-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

VITEK 2 was found to be compatible with validation tests for ESBL positivity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In this prospective study we aimed to compare the effectiveness of VITEK-2 (bioMérieux, France) automated system, double-disc synergy (DDST) versus combined disc test (CDT) in detecting the Extended-Spectrum Beta-Lactamase (ESBL) positivity in Escherichia coli and Klebsiella pneumoniae strains isolated from various clinical samples.
📊
Key Findings & Data:Susceptibility tests were performed with the VITEK 2 (BioMérieux, France) system before.
💡
Conclusion & Impact:VITEK 2 was found to be compatible with validation tests for ESBL positivity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Escherichia coli · Klebsiella pneumoniae · VITEK-2

Abstract

Aim: In this prospective study we aimed to compare the effectiveness of VITEK-2 (bioMérieux, France) automated system, double-disc synergy (DDST) versus combined disc test (CDT) in detecting the Extended-Spectrum Beta-Lactamase (ESBL) positivity in Escherichia coli and Klebsiella pneumoniae strains isolated from various clinical samples. Material and Method: E.coli and K. pneumoniae strains inoculated on Mueller Hinton Agar plate. Susceptibility tests were performed with the VITEK 2 (BioMérieux, France) system before. Afterward, EBSL positivity was investigated manually DDST and CDT. Minimal inhibitor concentration (MIC) results of three tests were compared with each other according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. Results: 184 E. coli and K.pneumoniae strains, elevated. 92.9% of 98 patients with VITEK 2 positive results were positive with combined disc and DDS method, 100% of the 86 patients with negative results of VITEK 2 were negative with combined disc and MDC. Conclusion: VITEK 2 was found to have a sensitivity of 100%, a specificity of 92.4%, a positive predictive value of 92.8% and a negative predictive value of 100%. VITEK 2 was found to be compatible with validation tests for ESBL positivity.

🔖

Cite This Article

YILMAZ, M., AK, Ö., HACISEYİTOĞLU, D., ALKAN, S. (2022). A comparative study of VITEK-2, Double Disc Synergy and Combined Disc Methods for detection of ESBL (Extended Spectrum Beta-Lactamase) production in Escherichia coli and Klebsiella pneumoniae strains. Journal of Contemporary Medicine, Cilt: 12 - Sayı: 1, 116–120. https://ajindex.com/articles/774900

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Forbes A, Sahm F, Weissfeld S. Principles of antimicrobial action and resistance, In: Fabiano K, Lester S, Wurm E(eds), Bailey & Scott’s Diagnostic Microbiology. 2003,11thed. St. Louis. CV Mosby Co, Missouri. p: 214-220
  2. Livermore DM.Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect. 2008;14 (1): 3-10
  3. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995; 8(4): 557-584
  4. Albertini M, Benoit C, Berardi L. Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended spectrum beta-lactamase (ESBL) in Northern France: a five-year multicentre incidence study. J Hosp Infect. 2002; 52(2):107-113
  5. Kang C, Kim SH, Park WB, et al. Bloodstream infections due to extended spectrum beta-lactamases producing E.coli and K.pneumoniae: Risk factors for treatment outcome with special emphasis on antimicrobial. Antimicrobial Agents Chemother. 2004; 48(12): 4574-4581
  6. Ramphal R, Ambrose PG. Extended spectrum beta-lactamases and clinical outcomes: Current data. Clin Inf Dis. 2006; 42 Suppl 4: 164-172
  7. Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: special needs for fastidious organisms and difficult-to-detect resistance mechanisms. Clin Infect Dis. 2000; 30(5): 799-808
  8. Clinical and Laboratory Standards Institute. Performance Standarts for Antimicrobial Susceptibility Testing. 24th Informational Supplement. CLSI Document M100-S24, CLSI, Wayne, PA, 2014
  9. Mehli M, Zer Y, Gayyurhan E. Çeşitli klinik örneklerden izole edilen Enterobacteriaceae suşlarında GSBL oluşturmanın ÇDST ve VITEK 2 yöntemleri ile araştırılması. ANKEM Derg. 2007; 21(3):71-75
  10. Fincancı M, Ulutürk R, Eren G, et al. Klebsiella pneumoniae, Klebsiella oxytoca ve Escherichia coli kökenlerinde genişletilmiş spektrumlu beta laktamazların araştırılmasında kullanılan çeşitli yöntemlerin karşılaştırılması. İnfeksiyon Derg. 2003;17(1):55-60
  11. Öztürk CE, Kaya DA, Yücel M,, et al. Genişlemiş Spektrumlu Beta-Laktamaz Tespitinde Kullanılan Bazı Fenotipik Testlerin Karşılaştırılması. ANKEM Derg. 2010;24(3):111-116
  12. Yavuz MT, Ersan G, Süvarierel M. Enterobacteriaceae kökenlerinde genişlemiş spektrumlu beta-laktamaz üretiminin iki farklı yöntemle araştırılması, Düzce Tıp Fak Derg. 2005;2:10-13
  13. Yurtman AN, Hoşgör-Limoncu M, Ermertcan Ş, et al. Genişlemiş spektrumlu beta-laktamazların saptanmasında fenotipik yöntemlerin karşılaştırılması. İnfeksiyon Derg. 2009;23(1